EBOS Group Limited (EBO.AX), which markets and distributes healthcare, medical, pharmaceutical and animal care products in Australia, on Thursday outlined its strategy, growth plans and capital priorities at an Investor Day in Sydney.
Over the next three years, the company expects capital expenditure to decline from fiscal 2027, supporting earnings per share growth from fiscal 2028 onwards, along with mid-single-digit organic underlying EBITDA growth.
The company said it has redeployed around $2 billion over the past five years into higher-growth businesses, including medical technology and animal care, as it continues to shift its portfolio toward higher-return segments.
It also reaffirmed a dividend payout of 60%-80% of underlying net profit after tax.
The group noted that capital expenditure is expected to peak in fiscal 2026 before easing from fiscal 2027.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.